Nicotinamide relaxes vascular smooth muscle by inhibiting myosin light chain kinase-dependent signaling pathways: Implications for anticancer efficacy

Oncology Research

Volumn 14, Issue 10, 2004, Pages 483-489

  Ruddock, Mark W ^a   Hirst, David G ^a,b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Myosin light chain kinase; Myosin light chains; Nicotinamide; Tumor radiosensitizer; Vascular smooth muscle

Indexed keywords

ACTIN; ANTINEOPLASTIC AGENT; CALMODULIN; IMMUNOGLOBULIN LIGHT CHAIN; MYOSIN; MYOSIN LIGHT CHAIN KINASE INHIBITOR; NICOTINAMIDE; PROTEIN KINASE (CALCIUM,CALMODULIN);

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM BINDING; CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; MALE; MIXED LYMPHOCYTE CULTURE; NONHUMAN; OXYGENATOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 9244250304     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/0965040042380478     Document Type: Article

References (26)

1. Kaanders, J. H.; Pop, L. A.; Marres, H. A.; Bruaset, I.; van den Hoogen, F. J.; Merkx, M. A.; van der Kogel, A. J. ARCON: Experience in 215 patients with advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 52:769-778; 2002.
2. Kaanders, J. H.; Bussink, J.; van der Kogel, A. J. ARCON: A novel biology-based approach in radiotherapy. Lancet Oncol. 3:728-737; 2002.
3. Bussink, J.; Kaanders, J. H.; Rijken, P. F.; Peters, J. P. W.; Hodgkiss, R. J.; Marres, H. A. M.; van der Kogel, A. J. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: Effects of carbogen and nicotinamide. Radiother. Oncol. 50:173-184; 1999.
4. Sibtain, A.; Hill, S.; Goodchild, K.; Shah, N.; Saunders, M.; Hoskin, P. J. The modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. Radiother. Oncol. 62:69-76; 2002.
5. Bussink, J.; Stratford, M. R.; van der Kogel, A. J.; Folkes, L. K.; Kaanders, J. H. Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. Radiother. Oncol. 63:285-291; 2002
6. Horsman, M. R.; Chaplin, D. J.; Brown, J. M. Tumour radiosensitization by nicotinamide: A result of improved perfusion and oxygenation. Radiat. Res. 118:139-150; 1989.
7. Hirst, D. G.; Kennovin, G. D.; Flitney, F. W. The radiosensitizer nicotinamide inhibits arterial vasoconstriction. Br. J. Radiol. 67:795-799; 1994.
8. Hirst, D. G.; Kennovin, G. D.; Tozer, G. M.; Prise, V. E.; Flitney, F. W. The modification of blood flow in tumours and their supplying arteries by nicotinamide. Acta Oncol. 34:397-400; 1995.
9. Ruddock, M. W.; Burns, D. M.; McKeown, S. R.; Murphy, L.; Walsh, I. K.; Keane, P. F. Contractile properties of human renal cell carcinoma recruited arteries and their response to nicotinamide. Radiother. Oncol. 54:179-184; 2000.
10. Ruddock, M. W.; Burns, D. M.; Murphy, L.; O'Rourke, M.; Hirst, D. G. The effect of nicotinamide on spontaneous and induced activity in smooth and skeletal muscle. Radiother. Oncol. 56:253-257; 2000.
11. Burns, D. M.; Ruddock, M. W.; Walker, M.; Hirst, D. G. Nicotinamide-inhibited vasoconstriction: Lack of dependence on agonist signalling pathways. Eur. J. Pharmacol. 374:213-220; 1999.
12. Burns, D. M.; Ruddock, M. W.; Brown, J. C. W.; Kennovin, G. D.; Hirst, D. G. The effect of the vasodilator nicotinamide on cyclic nucleotides in vascular smooth muscle. Biochem. Soc. Trans. 25:132S; 1997.
13. Saitoh, M.; Ishikawa, T.; Mattushuma, S.; Naka, M.; Hidaka, H. Selective inhibition of catalytic acivity of smooth muscle myosin light-chain kinase. J. Biol. Chem. 362:7796-7801; 1987.
14. Obata, N. H.; Okazaki, K.; Maeda, O.; Kikkawa, F.; Tomoda, Y.; Hidaka, H. Effect of KN-62, Ca2+/calmodulain-dependent protein kinase II inhibitor on adriamycin resistance of human ovarian cancer cells. Biochem. Biophys. Res. Commun. 1215:566-571; 1995.
15. Hartshorne, D. J. Biochemistry of the contractile process in smooth muscle. In: Johnson, L. R., ed. Physiology of the gastrointestinal tract. New York: Raven Press; 1987: 423-482.
16. Kamm, K. E.; Stull, J. T. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Annu. Rev. Pharmacol. Toxicol. 25:593-620; 1985.
17. Putkey, J. A.; Draetta, G. F.; Slaughter, G. R.; Klee, C. B.; Cohen, P.; Stull, J. T.; Means, A. R. Genetically engineered calmodulins differentially activate target enzymes. J. Biol. Chem. 261:9896-9903; 1986.
18. Shimizu, H.; Ito, M.; Miyahara, M.; Ichikawa, K.; Okubo, S.; Konishi, T.; Naka, M.; Tanaka, T.; Hirano, K.; Hartshorne, D. J.; et al. Characterisation of the myosin-binding subunit of smooth muscle phosphatase. J. Biol. Chem. 269:30407-30411; 1994.
19. Shirazi, A.; Iizuka, K.; Fadden, P. Purification and characterisation of the mammalian myosin light chain phosphatase holoenzyme. The differential effects of the holoenzyme and its subunits on smooth muscle. J. Biol. Chem. 269:31598-31606; 1994.
20. Stull, J. T.; Tansey, M. G.; Word, R. A.; Kubota, Y.; Kamm, K. E. Myoisn light chain kinase phosphorylation: Regulation of the calcium sensitivity of contractile elements. Adv. Exp. Med. Biol. 304:129-138; 1991.
21. Ito, I. Effects of KN-62, a specific inhibitor of calcium/ calmodulin-dependent protein kinase II, on long term potentiation in the rat hippocampus. Neurosci. Lett. 121: 119-121; 1990.
22. Tokumitsu, H.; Chijiwa, T.; Hagiwara, M.; Mizutani, A.; Terasawa, M.; Hidaka, H. KN-62, 1-[N,O-Bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4- phenylpiperazine, a specific inhibitor of calcium/calmodulin-dependent protein kinase II. J. Biol. Chem. 265:4315-4320; 1990.
23. Tansey, M. G.; Lubyphelps, K.; Kamm, K. E.; Stull, J. T. Calcium-dependent phosphorylation of myosin light chain kinase decreases the calcium sensitivity of light chain phosphorylation within smooth muscle cells. J. Biol. Chem. 269:9912-9920; 1994.
24. Whitney, G.; Throckmorton, D.; Isales, C.; Takuwa, Y.; Yeh, J.; Rasmussen, H.; Brophy, C. Kinase activation and smooth muscle contraction in the presence and absence of calcium. J. Vasc. Surg. 22:37-44; 1995.
25. Ishikawa, T.; Chijiwa, T.; Hagiwara, M.; Mamiya, S.; Saitoh, M.; Hidaka, H. ML-9 inhibits the vascular contraction via the inhibition of myosin light chain phosphorylation. Mol. Pharmacol. 33:598-603; 1998.
26. Watanabe, H.; Takahashi, R.; Zang, X. X.; Kakizawa, H.; Hayashi, H.; Ohno, R. Inhibition of agonist-induced calcium entry in endothelial cells by myosin light chain kinase inhibitor. Biochem. Biophys. Res. Commun. 225: 777-784; 1996.